Alzamend Neuro, Inc.
ALZN Nasdaq
SEC CIK 1677077
Follow Alzamend Neuro
Weekly email: filings, results, news
Net income
−$3M
−12% vs same quarter last year
EPS, diluted
−$0.68
+46.9% vs same quarter last year
Operating cash flow
−$1.1M
+51.8% vs same quarter last year
Operating income
−$3M
−12% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY26 | −$8.8M |
| FY25 | −$4.5M |
| FY24 | −$9.9M |
| FY23 | −$14.9M |
| FY22 | −$12.4M |
| FY21 | −$5M |
| FY20 | −$4.4M |
| FY19 | - |
News
No stories filed under Alzamend Neuro yet - coverage appears here as the news feed clusters it.